LA JOLLA PHARMACEUTICAL CO's ticker is LJPC and the CUSIP is 503459604. A total of 83 filers reported holding LA JOLLA PHARMACEUTICAL CO in Q1 2019. The put-call ratio across all filers is 1.57 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $811,000 | -55.0% | 86,009 | -4.0% | 0.00% | -50.0% |
| Q3 2018 | $1,804,000 | -24.8% | 89,615 | +9.0% | 0.00% | 0.0% |
| Q2 2018 | $2,398,000 | -3.0% | 82,212 | -0.9% | 0.00% | 0.0% |
| Q1 2018 | $2,472,000 | -9.2% | 82,992 | -1.9% | 0.00% | 0.0% |
| Q4 2017 | $2,721,000 | -75.6% | 84,566 | -73.6% | 0.00% | -80.0% |
| Q3 2017 | $11,154,000 | +14.9% | 320,720 | -0.2% | 0.01% | +11.1% |
| Q2 2017 | $9,704,000 | -13.0% | 321,330 | -12.4% | 0.01% | -18.2% |
| Q1 2017 | $11,156,000 | +23.7% | 366,802 | -28.7% | 0.01% | +37.5% |
| Q4 2016 | $9,019,000 | -28.2% | 514,466 | -3.1% | 0.01% | -33.3% |
| Q3 2016 | $12,569,000 | +38.6% | 531,048 | -6.3% | 0.01% | +20.0% |
| Q2 2016 | $9,070,000 | -16.0% | 566,890 | +9.8% | 0.01% | -16.7% |
| Q1 2016 | $10,801,000 | -18.1% | 516,517 | +6.7% | 0.01% | -20.0% |
| Q4 2015 | $13,185,000 | +1.4% | 484,267 | +3.5% | 0.02% | 0.0% |
| Q3 2015 | $13,000,000 | – | 467,797 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,872,130 | $77,548,000 | 30.77% |
| RTW INVESTMENTS, LP | 1,084,416 | $29,279,000 | 9.67% |
| Avoro Capital Advisors LLC | 784,199 | $21,173,000 | 7.29% |
| Broadfin Capital, LLC | 1,165,373 | $31,465,000 | 1.94% |
| P.A.W. CAPITAL CORP | 50,400 | $1,361,000 | 1.54% |
| Belmont Global Advisors, Inc. | 37,522 | $1,013,000 | 1.31% |
| Perceptive Advisors | 649,515 | $17,537,000 | 1.30% |
| ACUTA CAPITAL PARTNERS, LLC | 82,920 | $2,239,000 | 1.07% |
| Iguana Healthcare Management, LLC | 110,000 | $2,970,000 | 0.98% |
| Virtus ETF Advisers LLC | 10,250 | $277,000 | 0.76% |